• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

鉴定与 BRCA1 突变、免疫检查点和卵巢癌临床结局相关的免疫增强分子亚型。

Identification of immune-enhanced molecular subtype associated with BRCA1 mutations, immune checkpoints and clinical outcome in ovarian carcinoma.

机构信息

Department of Gynaecology and Obstetrics, Shengjing Hospital Affiliated to China Medical University, Shenyang, China.

Key Laboratory Of Maternal-Fetal Medicine of Liaoning Province, Key Laboratory of Obstetrics and Gynecology of Higher Education of Liaoning Province, Shenyang, China.

出版信息

J Cell Mol Med. 2020 Mar;24(5):2819-2831. doi: 10.1111/jcmm.14830. Epub 2020 Jan 29.

DOI:10.1111/jcmm.14830
PMID:31995855
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7077593/
Abstract

Ovarian carcinoma has the highest mortality among the malignant tumours in gynaecology, and new treatment strategies are urgently needed to improve the clinical status of ovarian carcinoma patients. The Cancer Genome Atlas (TCGA) cohort were performed to explore the immune function of the internal environment of tumours and its clinical correlation with ovarian carcinoma. Finally, four molecular subtypes were obtained based on the global immune-related genes. The correlation analysis and clinical characteristics showed that four subtypes were all significantly related to clinical stage; the immune scoring results indicated that most immune signatures were upregulated in C3 subtype, and the majority of tumour-infiltrating immune cells were upregulated in both C3 and C4 subtypes. Compared with other subtypes, C3 subtype had a higher BRCA1 mutation, higher expression of immune checkpoints, and optimal survival prognosis. These findings of the immunological microenvironment in tumours may provide new ideas for developing immunotherapeutic strategies for ovarian carcinoma.

摘要

卵巢癌是妇科恶性肿瘤中死亡率最高的肿瘤，迫切需要新的治疗策略来改善卵巢癌患者的临床状况。对癌症基因组图谱（TCGA）队列进行分析，以探讨肿瘤内部环境的免疫功能及其与卵巢癌的临床相关性。最后，基于全局免疫相关基因得到了四个分子亚型。相关性分析和临床特征表明，四个亚型均与临床分期显著相关；免疫评分结果表明，C3 亚型中大多数免疫特征上调，C3 和 C4 亚型中大多数肿瘤浸润免疫细胞上调。与其他亚型相比，C3 亚型具有更高的 BRCA1 突变率、更高的免疫检查点表达和最佳的生存预后。这些肿瘤免疫微环境的发现可能为开发卵巢癌的免疫治疗策略提供新的思路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d615/7077593/99678f3cf41c/JCMM-24-2819-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d615/7077593/ddc4ff232436/JCMM-24-2819-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d615/7077593/33d8a46ca7ca/JCMM-24-2819-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d615/7077593/32a751b05e7e/JCMM-24-2819-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d615/7077593/65dcc2118fb2/JCMM-24-2819-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d615/7077593/5b1207029926/JCMM-24-2819-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d615/7077593/9eec8ceea947/JCMM-24-2819-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d615/7077593/99678f3cf41c/JCMM-24-2819-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d615/7077593/ddc4ff232436/JCMM-24-2819-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d615/7077593/33d8a46ca7ca/JCMM-24-2819-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d615/7077593/32a751b05e7e/JCMM-24-2819-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d615/7077593/65dcc2118fb2/JCMM-24-2819-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d615/7077593/5b1207029926/JCMM-24-2819-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d615/7077593/9eec8ceea947/JCMM-24-2819-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d615/7077593/99678f3cf41c/JCMM-24-2819-g007.jpg

相似文献

1
Identification of immune-enhanced molecular subtype associated with BRCA1 mutations, immune checkpoints and clinical outcome in ovarian carcinoma.鉴定与 BRCA1 突变、免疫检查点和卵巢癌临床结局相关的免疫增强分子亚型。
J Cell Mol Med. 2020 Mar;24(5):2819-2831. doi: 10.1111/jcmm.14830. Epub 2020 Jan 29.
2
Two immune-enhanced molecular subtypes differ in inflammation, immune checkpoints, mutations, and prognostic outcome in stage I-II colonic carcinoma.两种免疫增强分子亚型在I-II期结肠癌的炎症、免疫检查点、突变及预后结果方面存在差异。
J Biochem Mol Toxicol. 2021 Apr;35(4):e22703. doi: 10.1002/jbt.22703. Epub 2021 Jan 6.
3
A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma.BRCA1/2突变特征与高级别浆液性卵巢癌的生存情况
Cancer Epidemiol Biomarkers Prev. 2016 Nov;25(11):1511-1516. doi: 10.1158/1055-9965.EPI-16-0286. Epub 2016 Aug 5.
4
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.BRCA1/2基因突变状态与高级别浆液性卵巢癌新抗原负荷、肿瘤浸润淋巴细胞数量及PD-1/PD-L1表达的相关性及预后意义
Oncotarget. 2016 Mar 22;7(12):13587-98. doi: 10.18632/oncotarget.7277.
5
Identification of immune microenvironment subtypes that predicted the prognosis of patients with ovarian cancer.鉴定预测卵巢癌患者预后的免疫微环境亚型。
J Cell Mol Med. 2021 Apr;25(8):4053-4061. doi: 10.1111/jcmm.16374. Epub 2021 Mar 6.
6
An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.从免疫角度探索 BRCA1 和 BRCA2 种系突变相关的乳腺癌和卵巢癌。
BMC Cancer. 2020 Mar 12;20(1):197. doi: 10.1186/s12885-020-6605-1.
7
Identification of metabolism-associated molecular subtype in ovarian cancer.卵巢癌代谢相关分子亚型的鉴定。
J Cell Mol Med. 2021 Oct;25(20):9617-9626. doi: 10.1111/jcmm.16907. Epub 2021 Sep 15.
8
The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.BRCAness 在丹麦基于人群的上皮性卵巢癌队列中的临床重要性。
Int J Gynecol Cancer. 2019 Jan;29(1):166-173. doi: 10.1136/ijgc-2018-000017.
9
Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours.
Genes Chromosomes Cancer. 1999 Jun;25(2):91-6. doi: 10.1002/(sici)1098-2264(199906)25:2<91::aid-gcc3>3.0.co;2-5.
10
Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses.乳腺癌和卵巢癌中 BRCA 的表达与突变：生物信息学分析证据。
Int J Mol Med. 2018 Dec;42(6):3542-3550. doi: 10.3892/ijmm.2018.3870. Epub 2018 Sep 11.

引用本文的文献

1
BRCA1 and Its Vulnerable C-Terminal BRCT Domain: Structure, Function, Genetic Mutations and Links to Diagnosis and Treatment of Breast and Ovarian Cancer.BRCA1及其易损的C端BRCT结构域：结构、功能、基因突变以及与乳腺癌和卵巢癌诊断与治疗的关联
Pharmaceuticals (Basel). 2024 Mar 4;17(3):333. doi: 10.3390/ph17030333.
2
Innovative molecular subtypes of multiple signaling pathways in colon cancer and validation of FMOD as a prognostic-related marker.结肠癌中多种信号通路的创新分子亚型及FMOD作为预后相关标志物的验证
J Cancer Res Clin Oncol. 2023 Nov;149(14):13087-13106. doi: 10.1007/s00432-023-05163-6. Epub 2023 Jul 20.
3

本文引用的文献

1
Integrated multi-omics analysis of genomics, epigenomics, and transcriptomics in ovarian carcinoma.卵巢癌基因组学、表观基因组学和转录组学的综合多组学分析
Aging (Albany NY). 2019 Jun 29;11(12):4198-4215. doi: 10.18632/aging.102047.
2
EmExplorer: a database for exploring time activation of gene expression in mammalian embryos.EmExplorer：一个用于探索哺乳动物胚胎中基因表达时间激活的数据库。
Open Biol. 2019 Jun 28;9(6):190054. doi: 10.1098/rsob.190054. Epub 2019 Jun 5.
3
RAP80 expression in breast cancer and its relationship with apoptosis in breast cancer cells.
COL19A1 is a predictive biomarker for the responsiveness of esophageal squamous cell carcinoma patients to immune checkpoint therapy.
COL19A1 是预测食管鳞癌患者对免疫检查点治疗反应性的生物标志物。
Thorac Cancer. 2023 May;14(14):1294-1305. doi: 10.1111/1759-7714.14873. Epub 2023 Apr 2.
4
Definition of immune molecular subtypes with distinct immune microenvironment, recurrence, and PANoptosis features to aid clinical therapeutic decision-making.具有不同免疫微环境、复发和全凋亡特征的免疫分子亚型的定义，以辅助临床治疗决策。
Front Genet. 2022 Oct 13;13:1007108. doi: 10.3389/fgene.2022.1007108. eCollection 2022.
5
Early Stage Finding of an Immune-Enhanced Genetic Subtype of Nonsmall Cell Lung Cancer Related with T-Cell Depletion.与T细胞耗竭相关的非小细胞肺癌免疫增强基因亚型的早期发现
Evid Based Complement Alternat Med. 2022 Oct 14;2022:6765997. doi: 10.1155/2022/6765997. eCollection 2022.
6
Metabolic pathway-based molecular subtyping of colon cancer reveals clinical immunotherapy potential and prognosis.基于代谢途径的结肠癌分子亚型揭示了临床免疫治疗的潜力和预后。
J Cancer Res Clin Oncol. 2023 Jun;149(6):2393-2416. doi: 10.1007/s00432-022-04070-6. Epub 2022 Jun 22.
7
Molecular Typing of Gastric Cancer Based on Invasion-Related Genes and Prognosis-Related Features.基于侵袭相关基因和预后相关特征的胃癌分子分型
Front Oncol. 2022 Jun 3;12:848163. doi: 10.3389/fonc.2022.848163. eCollection 2022.
8
Tumor Immune Microenvironment Related Gene-Based Model to Predict Prognosis and Response to Compounds in Ovarian Cancer.基于肿瘤免疫微环境相关基因的模型预测卵巢癌预后及对化合物的反应
Front Oncol. 2021 Dec 13;11:807410. doi: 10.3389/fonc.2021.807410. eCollection 2021.
9
Comprehensive analysis of prognostic immune-related genes and drug sensitivity in cervical cancer.宫颈癌预后免疫相关基因及药物敏感性的综合分析
Cancer Cell Int. 2021 Dec 1;21(1):639. doi: 10.1186/s12935-021-02333-9.
10
Identification of metabolism-associated molecular subtype in ovarian cancer.卵巢癌代谢相关分子亚型的鉴定。
J Cell Mol Med. 2021 Oct;25(20):9617-9626. doi: 10.1111/jcmm.16907. Epub 2021 Sep 15.
RAP80在乳腺癌中的表达及其与乳腺癌细胞凋亡的关系。
Onco Targets Ther. 2019 Jan 18;12:625-634. doi: 10.2147/OTT.S186981. eCollection 2019.
4
Hereditary breast cancer; Genetic penetrance and current status with BRCA.遗传性乳腺癌；BRCA 基因的遗传外显率和现状。
J Cell Physiol. 2019 May;234(5):5741-5750. doi: 10.1002/jcp.27464. Epub 2018 Dec 14.
5
Response to: The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers.回应：GPRC5A 移码变异体 c.183del 与 BRCA1 突变携带者患乳腺癌风险增加无关。
Int J Cancer. 2019 Apr 1;144(7):1758-1760. doi: 10.1002/ijc.32013. Epub 2019 Jan 6.
6
Clinical significance of the immune microenvironment in ovarian cancer patients.卵巢癌患者免疫微环境的临床意义。
Mol Omics. 2018 Oct 8;14(5):341-351. doi: 10.1039/c8mo00128f.
7
iRNA-2OM: A Sequence-Based Predictor for Identifying 2'-O-Methylation Sites in Homo sapiens.iRNA-2OM：一种用于识别人类2'-O-甲基化位点的基于序列的预测工具。
J Comput Biol. 2018 Nov;25(11):1266-1277. doi: 10.1089/cmb.2018.0004. Epub 2018 Aug 16.
8
Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.CBCSG006 试验的生物标志物评估：顺铂加吉西他滨与紫杉醇加吉西他滨作为转移性三阴性乳腺癌一线治疗的随机 III 期试验。
Ann Oncol. 2018 Aug 1;29(8):1741-1747. doi: 10.1093/annonc/mdy209.
9
Specific breast cancer prognosis-subtype distinctions based on DNA methylation patterns.基于 DNA 甲基化模式的特定乳腺癌预后亚型区分。
Mol Oncol. 2018 Jun;12(7):1047-1060. doi: 10.1002/1878-0261.12309. Epub 2018 May 21.
10
Two immune-enhanced molecular subtypes differ in inflammation, checkpoint signaling and outcome of advanced head and neck squamous cell carcinoma.两种免疫增强分子亚型在炎症、检查点信号传导及晚期头颈部鳞状细胞癌的预后方面存在差异。
Oncoimmunology. 2017 Nov 6;7(2):e1392427. doi: 10.1080/2162402X.2017.1392427. eCollection 2018.